TriSalus Life Sciences (TLSI) FCF Margin (2022 - 2026)

TriSalus Life Sciences' FCF Margin history runs 5 years deep, the most recent figure standing at 74.4% for Q1 2026.

• On a quarterly basis, FCF Margin fell 2437.0% year-over-year to 74.4% in Q1 2026; TTM through Mar 2026 was 44.82%, a 6251.0% increase from a year earlier, with the FY2025 full-year figure at 40.04%, up 9873.0% from the prior year.
• FCF Margin declined to 74.4% in Q1 2026 per TLSI's latest filing, from 12.68% in the prior quarter.
• Across five years, FCF Margin topped out at 12.68% in Q4 2025 and bottomed at 583.23% in Q3 2022.
• The 5-year median for FCF Margin is 166.91% (2023), against an average of 185.13%.
• Across the five-year window, FCF Margin soared 27067 bps in 2024 and slumped 2437 bps in 2026, its largest moves.
• Year by year, FCF Margin stood at 243.99% in 2022, then soared by 32 bps to 166.91% in 2023, then jumped by 61 bps to 65.51% in 2024, then surged by 81 bps to 12.68% in 2025, then slumped by 487 bps to 74.4% in 2026.
• Per Business Quant, the three latest TLSI FCF Margin figures stand at 74.4% (Q1 2026), 12.68% (Q4 2025), and 39.48% (Q3 2025).